CN106148498B - Kras基因突变检测试剂盒及其应用 - Google Patents
Kras基因突变检测试剂盒及其应用 Download PDFInfo
- Publication number
- CN106148498B CN106148498B CN201510165672.2A CN201510165672A CN106148498B CN 106148498 B CN106148498 B CN 106148498B CN 201510165672 A CN201510165672 A CN 201510165672A CN 106148498 B CN106148498 B CN 106148498B
- Authority
- CN
- China
- Prior art keywords
- seq
- kras gene
- kit
- mutation
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150105104 Kras gene Proteins 0.000 title claims abstract description 49
- 238000001514 detection method Methods 0.000 title claims abstract description 38
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 32
- 239000000523 sample Substances 0.000 claims abstract description 31
- 230000035772 mutation Effects 0.000 claims abstract description 30
- 230000003321 amplification Effects 0.000 claims abstract description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 14
- 230000000903 blocking effect Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012257 pre-denaturation Methods 0.000 claims description 4
- 239000013558 reference substance Substances 0.000 claims description 4
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 101100086477 Homo sapiens KRAS gene Proteins 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 2
- 101150096316 5 gene Proteins 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000012188 paraffin wax Substances 0.000 abstract 1
- 210000000115 thoracic cavity Anatomy 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 35
- 201000011510 cancer Diseases 0.000 description 21
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 13
- 206010009944 Colon cancer Diseases 0.000 description 12
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 12
- 102100030708 GTPase KRas Human genes 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 238000001712 DNA sequencing Methods 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 206010069755 K-ras gene mutation Diseases 0.000 description 4
- 239000007984 Tris EDTA buffer Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101150044182 8 gene Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 101150040459 RAS gene Proteins 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 102200006532 rs112445441 Human genes 0.000 description 2
- 102200006531 rs121913529 Human genes 0.000 description 2
- 102200006537 rs121913529 Human genes 0.000 description 2
- 102200006539 rs121913529 Human genes 0.000 description 2
- 102200006538 rs121913530 Human genes 0.000 description 2
- 102200006540 rs121913530 Human genes 0.000 description 2
- 102200006541 rs121913530 Human genes 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- NZCHHEFOTMKOJX-UHFFFAOYSA-K [6-[[3-carboxy-4-(3-oxido-6-oxoxanthen-9-yl)phenyl]carbamothioylamino]hexoxy-oxidophosphoryl] [5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound O1C(COP([O-])(=O)OP([O-])(=O)OCCCCCCNC(=S)NC=2C=C(C(=CC=2)C2=C3C=CC(=O)C=C3OC3=CC([O-])=CC=C32)C(O)=O)C(O)C(O)C1N1C=CC(=O)NC1=O NZCHHEFOTMKOJX-UHFFFAOYSA-K 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- -1 dNTP Proteins 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510165672.2A CN106148498B (zh) | 2015-04-09 | 2015-04-09 | Kras基因突变检测试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510165672.2A CN106148498B (zh) | 2015-04-09 | 2015-04-09 | Kras基因突变检测试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106148498A CN106148498A (zh) | 2016-11-23 |
CN106148498B true CN106148498B (zh) | 2020-05-12 |
Family
ID=57335738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510165672.2A Active CN106148498B (zh) | 2015-04-09 | 2015-04-09 | Kras基因突变检测试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106148498B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107164543A (zh) * | 2017-06-16 | 2017-09-15 | 上海长海医院 | Kras 作为胰腺癌中生物标志物的用途 |
CN107151706A (zh) * | 2017-06-27 | 2017-09-12 | 郴州市第人民医院 | 一种检测血浆游离dna中kras基因突变的试剂盒及方法 |
CN107447013B (zh) * | 2017-08-31 | 2020-06-05 | 上海伯豪生物技术有限公司 | 检测Kras基因第12、13密码子突变位点的方法及其试剂盒 |
CN108374008A (zh) * | 2018-05-07 | 2018-08-07 | 求臻医学科技(北京)有限公司 | 用于检测kras突变的引物对和探针的组合产品、组合物、试剂盒及其应用 |
CN108441562A (zh) * | 2018-05-10 | 2018-08-24 | 中国科学院苏州纳米技术与纳米仿生研究所 | 检测Kras基因突变的引物、探针、试剂盒及应用 |
CN109439756A (zh) * | 2018-11-30 | 2019-03-08 | 广东腾飞基因科技股份有限公司 | 一种用于检测kras相关抗药性的试剂盒 |
CN110592217A (zh) * | 2019-10-08 | 2019-12-20 | 湖南艾佳生物科技股份有限公司 | 一种检测外周血游离dna中kras基因突变的试剂盒及其应用 |
CN110982886A (zh) * | 2019-12-30 | 2020-04-10 | 武汉光谷联合医学检验所股份有限公司 | 一种人类K-ras基因突变检测试剂盒及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102234686A (zh) * | 2010-04-23 | 2011-11-09 | 广州益善生物技术有限公司 | 一种kras基因突变检测液相芯片 |
CN102747158A (zh) * | 2012-07-16 | 2012-10-24 | 武汉海吉力生物科技有限公司 | 一种人类K-ras基因突变分型荧光定量PCR检测试剂盒及检测方法 |
CN102796811A (zh) * | 2011-05-26 | 2012-11-28 | 上海赛安生物医药科技有限公司 | 检测kras突变的试剂及方法 |
CN102888466A (zh) * | 2012-10-30 | 2013-01-23 | 武汉友芝友生物制药有限公司 | Kras基因突变检测试剂盒及检测方法 |
-
2015
- 2015-04-09 CN CN201510165672.2A patent/CN106148498B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102234686A (zh) * | 2010-04-23 | 2011-11-09 | 广州益善生物技术有限公司 | 一种kras基因突变检测液相芯片 |
CN102796811A (zh) * | 2011-05-26 | 2012-11-28 | 上海赛安生物医药科技有限公司 | 检测kras突变的试剂及方法 |
CN102747158A (zh) * | 2012-07-16 | 2012-10-24 | 武汉海吉力生物科技有限公司 | 一种人类K-ras基因突变分型荧光定量PCR检测试剂盒及检测方法 |
CN102888466A (zh) * | 2012-10-30 | 2013-01-23 | 武汉友芝友生物制药有限公司 | Kras基因突变检测试剂盒及检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106148498A (zh) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106148498B (zh) | Kras基因突变检测试剂盒及其应用 | |
CN104946739B (zh) | Egfr基因突变检测试剂盒及其应用 | |
CN108048531B (zh) | 一种高灵敏度检测稀有突变的超阻滞荧光定量pcr方法 | |
CN107419018B (zh) | 一种基于Blocker引物和ARMS引物检测基因突变的方法和试剂盒 | |
CN104818320B (zh) | 一次性检测肺癌多重基因的引物、探针、检测体系和试剂盒 | |
CN106103742B (zh) | 一种富集循环肿瘤dna的方法和试剂 | |
CN111088365B (zh) | 一种用于检测甲状腺癌ret基因突变及融合的引物及试剂盒 | |
WO2017185767A1 (zh) | 一组检测Kras基因突变的引物和探针及其试剂盒 | |
KR20150067151A (ko) | 암을 스크리닝하는 방법 | |
CN110951828A (zh) | 一种引物和探针的设计方法 | |
WO2011035538A1 (zh) | 用于定量检测egfr突变的试剂盒 | |
CN107513578A (zh) | 一种用于肺癌驱动基因及易感基因早筛的核酸质谱检测方法 | |
CN103773837A (zh) | 一种pik3ca基因突变荧光定量pcr检测试剂盒及检测方法 | |
Galot et al. | Current applications and challenges of circulating tumor DNA (ctDNA) in squamous cell carcinoma of the head and neck (SCCHN) | |
CN102776286A (zh) | 用于检测ros1基因融合突变的引物、探针及检测试剂盒 | |
CN105803076A (zh) | 检测egfr基因t790m位点的特异性引物及探针 | |
CN105441533A (zh) | Pik3ca基因突变检测体系及其试剂盒 | |
CN106148497A (zh) | Braf基因突变检测试剂盒及其应用 | |
CN106399514A (zh) | Nras基因突变检测试剂盒 | |
WO2011079524A1 (zh) | 用于定量检测k-ras突变的试剂盒 | |
CN116445621A (zh) | 同时检测肺癌和结直肠癌的dna和rna流程引物组和试剂盒 | |
CN111154883B (zh) | 一种乳腺癌相关基因PIK3CA位点g.179220986A>T突变体及其应用 | |
CN112251515B (zh) | 一种检测甲状腺癌靶向用药相关基因变异的引物及试剂盒 | |
CN113881759A (zh) | Egfr基因突变检测试剂盒及其检测方法 | |
CN109913481B (zh) | PIK3CA基因g.179224821G>A突变及其在乳腺癌辅助诊断中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: SHANGHAI JIYUAN BIOTECHNOLOGY CO.,LTD. Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: SHANGHAI JIYUAN BIOTECHNOLOGY CO.,LTD. Document name: the First Notification of an Office Action |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: SHANGHAI JIYUAN BIOTECHNOLOGY CO.,LTD. Document name: Notification to Go Through Formalities of Registration |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: SHANGHAI JIYUAN BIOTECHNOLOGY Co.,Ltd. Document name: Notification of Decision on Request for Restoration of Right |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Cao Jie Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Cao Jie Document name: Notice of termination of patent right |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Cao Jie Document name: Notice of resumption of claim approval |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Cao Jie Document name: payment instructions |
|
DD01 | Delivery of document by public notice |
Addressee: Cao Jie Document name: payment instructions |